# A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

> **NCT06095115** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 684 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** JNJ-77242113
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06095115
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-12
- **Primary completion:** 2024-07-29
- **Final completion:** 2027-04-06
- **Target enrollment:** 684 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06095115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06095115, "A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06095115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*